Literature DB >> 31307938

Response to Crizotinib Re-administration After Progression on Lorlatinib in a Patient With ALK-rearranged Non-small-cell Lung Cancer.

Jun Sakakibara-Konishi1, Hidenori Kitai2, Yasuyuki Ikezawa3, Yutaka Hatanaka4, Takaaki Sasaki5, Ryohei Yoshida5, Shinichi Chiba6, Shingo Matsumoto7, Koichi Goto8, Hidenori Mizugaki2, Naofumi Shinagawa2.   

Abstract

Entities:  

Keywords:  ALK-TKI; MET; Mutation; NGS; Sequential treatment

Mesh：

Substances：

Year:  2019        PMID： 31307938     DOI： 10.1016/j.cllc.2019.06.021

Source DB:  PubMed          Journal:  Clin Lung Cancer        ISSN： 1525-7304            Impact factor:   4.785


× No keyword cloud information.
  2 in total

1.  The Impact of Comprehensive Genomic Profiling (CGP) on the Decision-Making Process in the Treatment of ALK-Rearranged Advanced Non-Small Cell Lung Cancer (aNSCLC) After Failure of 2nd/3rd-Generation ALK Tyrosine Kinase Inhibitors (TKIs).

Authors:  Ari Raphael; Amir Onn; Liran Holtzman; Julia Dudnik; Damien Urban; Waleed Kian; Aharon Y Cohen; Mor Moskovitz; Alona Zer; Jair Bar; Natalie Maimon Rabinovich; Shirly Grynberg; Cecilie Oedegaard; Abed Agbarya; Nir Peled; Tzippy Shochat; Elizabeth Dudnik
Journal:  Front Oncol       Date:  2022-05-13       Impact factor: 5.738

2.  MET Alterations Are a Recurring and Actionable Resistance Mechanism in ALK-Positive Lung Cancer.

Authors:  Ibiayi Dagogo-Jack; Satoshi Yoda; Alice T Shaw; Aaron N Hata; Jochen K Lennerz; Adam Langenbucher; Jessica J Lin; Marguerite M Rooney; Kylie Prutisto-Chang; Audris Oh; Nathaniel A Adams; Beow Y Yeap; Emily Chin; Andrew Do; Hetal D Marble; Sara E Stevens; Subba R Digumarthy; Ashish Saxena; Rebecca J Nagy; Cyril H Benes; Christopher G Azzoli; Michael S Lawrence; Justin F Gainor
Journal:  Clin Cancer Res       Date:  2020-02-21       Impact factor: 12.531
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.